MYC and neuroblastoma: In vivo, GSK461364 treatment (50 mg/kg body weight intraperitoneally administered) strongly delayed the establishment of high-risk NB tumors in nude mice (by 22 days) irrespective of MYC status of the cell lines used, and significantly increased survival time in the treated group [906].